Hemolytic Uremic Syndrome: A Covid-19 Vaccine Reaction Case Report.
Main Article Content
Keywords
AstraZeneca, Acute Kidney Injury, Vaccine Reaction, Case report, Hemolytic Anaemia, Thrombocytopenia, Chimpanzee Platform
Abstract
The World Health Organization declared the Coronavirus disease of 2019 (COVID-19) a public health emergency of international concern on 30 January 2020, and a pandemic on 11 March 2020. Vaccines have proven to be vital in the effort to control and possibly eventually eradicate this viral infection. There have been reports of thromboembolic events associated with the use of vaccine but from available information, no reported case of atypical Hemolytic Uremic syndrome (HUS) in a black male has been described. We report a case of a 43-year-old black male Sub-Saharan African who presented with chills, fever, and generalized body aches of 3 days duration after receiving the second booster dose of the COVID-19 vaccine. He developed thrombocytopenia, hemolytic anaemia, and acute kidney injury on admission, and an initial diagnosis of malaria was made. He was managed with parenteral artesunate and then oral artemether/lumefantrine. His hemolytic anaemia was thought to be from malaria-associated hemolysis. This diagnosis was however later re-evaluated to hemolytic uremic syndrome and managed with 50mg daily oral prednisolone which resolved, and he resumed work a week later. Although mass vaccination is a key strategy to control the spread of COVID-19, critical observations should be made to confirm the risk of trigger for abnormal complement activation. Further observations should be made especially if it is a chimpanzee adenovirus-vectored vaccine.
References
2. Ishihara T, Ozawa H. Hemolytic uremic syndrome and encephalopathy from Shiga toxin-producing Escherichia coli. CMAJ. 2019 Jul 22;191(29):E81. doi: 10.1503/cmaj.190155
3. Stühlinger W, Kourilsky O, Kanfer A, Sraer JD. Letter: Haemolytic-uraemic syndrome: evidence for intravascular C3 activation. Lancet. 1974;2(7883):788-9.
4. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3):831-46.
5. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6:60. doi: 10.1186/1750-1172-6-60.
6. NorisM, Remuzzi G.Atypical hemolytic–uremic syndrome. New England Journal of Medicine, 2009. 361(17): 1676-1687.
7. World Health Organisation (WHO).Draft landscape of COVID-19 candidate vaccines. 2020. WHO https://www. who. int/publications/m/item/dr aft-landscape-of-covid-19-candidatevaccines, 2020.
8. WHO, Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19(AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™.https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-AZD1222GRADE-ETR-2021.1 2021.
9. Alexander JL, Moran GW, Gaya DR, Raine T, Hart A, Kennedy NA, Lindsay JO, MacDonald J, Segal JP, Sebastian S, Selinger CP, Parkes M, Smith PJ, Dhar A, Subramanian S, Arasaradnam R, Lamb CA, Ahmad T, Lees CW, Dobson L, Wakeman R, Iqbal TH, Arnott I, Powell N; Inflammatory Bowel Disease section of the British Society of Gastroenterology and the the Inflammatory Bowel Disease Clinical Research Group. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8.
10. AstraZeneca, UK and EU regulatory agencies confirm COVID-19 Vaccine AstraZeneca is safe and effective. 2021.
11. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021 Jun 3;384(22):2092-2101.
12. Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, Wiedmann M, Aamodt AH, Skattør TH, Tjønnfjord GE, Holme PA. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021 Jun 3;384(22):2124-2130.
13. Ferrer F, Roldão M, Figueiredo C, Lopes K. Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion. Nephron. 2022;146(2):185-189..
14. Lin IH, Chen YJ, Chang PY, Hsiao PW, Weng TH, Chang YH. Bilateral proliferative retinopathy and ischemic optic neuropathy in a patient with atypical hemolytic-uremic syndrome: A case report. Medicine (Baltimore). 2019 Sep;98(39):e17232. doi: 10.1097/MD.0000000000017232.
15. Mittal N, Hartemayer R, Jandeska S, Giordano L. Steroid Responsive Atypical Hemolytic Uremic Syndrome Triggered by Influenza B Infection. J Pediatr Hematol Oncol. 2019 Jan;41(1):e63-e67.
16. Lesesve JF, Salignac S, Alla F, Defente M, Benbih M, Bordigoni P, Lecompte T. Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. Am J Clin Pathol. 2004 May;121(5):739-45.
17. Gillet P, Mori M, Van den Ende J, Jacobs J. Buffer substitution in malaria rapid diagnostic tests causes false-positive results. Malar J. 2010 Jul 22;9:215. doi: 10.1186/1475-2875-9-215.